Search

Displaying results 3621 - 3630 of 10000 in total
  1. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  2. Drug

    Dimethyl sulfone

    go.drugbank.com/drugs/DB14090
    Investigational

    Mixtures: flexijoint 3-in-1 Joint Care Powder, OSTEOACTIV 3-in-1 Joint Formula Powder
  3. Drug

    AV608

    go.drugbank.com/drugs/DB05072
    Investigational

    AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).

  4. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    [A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

  5. Drug

    AZD-6482

    go.drugbank.com/drugs/DB14980
    Investigational

    AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  6. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  7. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. … This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.

    Products: Anzemet Injection 20 mg/ml
  8. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.

  9. Drug

    Amyl Nitrite

    go.drugbank.com/drugs/DB01612
    Approved

    Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. … As an inhalant, it also has psychoactive effect which has led to illegal drug use.

    Products: AMYL NITRITE INHALANT USP 0.3 ml/ampoule, Amyl Nitrite Vitrellae Bpc Liq 0.33 Ml/cap
  10. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.